Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Minimal Residual Disease”

451 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 451 results

Testing effectiveness (Phase 2)Looking for participantsNCT05286957
What this trial is testing

MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC

Who this might be right for
NSCLC
The First Affiliated Hospital of Zhengzhou University 60
Post-approval studies (Phase 4)Study completedNCT00199004
What this trial is testing

Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab

Who this might be right for
Adult Acute Lymphocytic Leukemia
Johann Wolfgang Goethe University Hospital 60
Not applicableUnknownNCT05254821
What this trial is testing

Cell-free Tumor DNA as Minimal Residual Disease in Hodgkin Lymphoma Patients

Who this might be right for
Hodgkin Lymphoma
Federico II University 130
Testing effectiveness (Phase 2)Study completedNCT00199030
What this trial is testing

Treatment of Relapsed T-cell Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma With MabCampath

Who this might be right for
Adult Acute Lymphocytic Leukemia T-cellLymphoma, Lymphoblastic
Goethe University 8
Testing effectiveness (Phase 2)Looking for participantsNCT03965234
What this trial is testing

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

Who this might be right for
Metastatic Bone SarcomaMetastatic Malignant Neoplasm in the LungMetastatic Soft Tissue Sarcoma+3 more
Roswell Park Cancer Institute 99
Early research (Phase 1)Study completedNCT04634435
What this trial is testing

Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Biohaven Pharmaceuticals, Inc. 7
Testing effectiveness (Phase 2)Looking for participantsNCT06189833
What this trial is testing

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS

Who this might be right for
Multiple Myeloma
Stichting European Myeloma Network 200
Testing effectiveness (Phase 2)Looking for participantsNCT06414148
What this trial is testing

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

Who this might be right for
Relapsed/Refractory Large B-cell Lymphoma
Peter MacCallum Cancer Centre, Australia 40
Testing effectiveness (Phase 2)Looking for participantsNCT07136077
What this trial is testing

Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Who this might be right for
Minimal Residual DiseaseAdjuvant ChemotherapyColorectal Cancer+3 more
M.D. Anderson Cancer Center 20
Not applicableLooking for participantsNCT06693830
What this trial is testing

CtDNA-guided Therapy Optimization in Newly Diagnosed DLBCL

Who this might be right for
LymphomaLymphoma, B-CellDiffuse Large B Cell Lymphoma+2 more
Hua-Jay J Cherng, MD 40
Not applicableActive Not RecruitingNCT06157216
What this trial is testing

Minimal Residual Disease-guided Adjuvant Therapy for Gastric Cancer

Who this might be right for
Stage II-III Gastric Cancer
Qilu Hospital of Shandong University 85
Testing effectiveness (Phase 2)Looking for participantsNCT06993675
What this trial is testing

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

Who this might be right for
Multiple Myeloma
Noffar Bar 50
Early research (Phase 1)Ended earlyNCT01743807
What this trial is testing

Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

Who this might be right for
Relapsed Acute Lymphoblastic LeukemiaRelapsed Acute Myelogenous Leukemia
Therapeutic Advances in Childhood Leukemia Consortium 4
Not applicableLooking for participantsNCT05000801
What this trial is testing

Clinical Study of DC-AML Cells in the Treatment of Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Affiliated Hospital to Academy of Military Medical Sciences 20
Testing effectiveness (Phase 2)Ended earlyNCT02767934
What this trial is testing

Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia

Who this might be right for
B Acute Lymphoblastic LeukemiaMinimal Residual DiseaseRecurrent Acute Lymphoblastic Leukemia+1 more
University of Washington 12
Testing effectiveness (Phase 2)Looking for participantsNCT06426511
What this trial is testing

CtDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC

Who this might be right for
Lung Cancer, Nonsmall Cell
Sun Yat-sen University 80
Testing effectiveness (Phase 2)Study completedNCT02067143
What this trial is testing

MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate

Who this might be right for
Untreated Philadelphia Positive Acute Lymphoblastic LeukemiaDe NovoSecondary+1 more
Gruppo Italiano Malattie EMatologiche dell'Adulto 204
Testing effectiveness (Phase 2)Looking for participantsNCT06083844
What this trial is testing

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

Who this might be right for
Ovarian Cancer
M.D. Anderson Cancer Center 20
Early research (Phase 1)Study completedNCT05040568
What this trial is testing

A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)

Who this might be right for
Colon CancerResected Stage
M.D. Anderson Cancer Center 15
Large-scale testing (Phase 3)Study completedNCT00179829
What this trial is testing

WT1 for the Detection of Minimal Residual Disease

Who this might be right for
LeukemiaCancer
Ann & Robert H Lurie Children's Hospital of Chicago 50
Load More Results